Aron Adkins, MD
Endocrinology, Diabetes & Metabolism · Eau Claire, WINPI 1336246529
Payments from drug & device makers
Across 808 payments — averaging $432.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$170K
- Dexcom, Inc.$58K
- AstraZeneca$41K
- Bayer$26K
- Medtronic$19K
- Abbott$16K
- plus $19K from 12 others
What the payments were for
- Consulting fees$5,2502%
- Speaking & faculty fees$310,30089%
- Travel & lodging$21,9176%
- Food & beverage$11,6953%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 510 | $169,752 |
| Dexcom, Inc. | 77 | $58,050 |
| AstraZeneca | 73 | $40,727 |
| Bayer | 28 | $25,994 |
| Medtronic(2 entities) | 53 | $19,067 |
| Abbott | 32 | $16,217 |
| Johnson & Johnson | 10 | $13,839 |
| Cequr Corporation | 5 | $5,154 |
| Tandem Diabetes Care, Inc. | 6 | $136 |
| Companion Medical, Inc. | 1 | $100 |
| Corcept Therapeutics | 3 | $60 |
| Amgen(2 entities) | 3 | $57 |
| Lilly USA, LLC | 2 | $28 |
| Sequel Med Tech, LLC | 1 | $22 |
| Intuity Medical Inc | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $11 |
| Senseonics, Incorporated | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$73,495
- RYBELSUS$55,913
- DEXCOM G7 GSS (161)$47,934
- FARXIGA$39,494
- Kerendia$24,215
- Tresiba$21,909
- DEXCOM STELO GLUCOSE BIOSENSOR$16,565
- INVOKANA$13,647
- FREESTYLE LIBRE 3$8,804
- DEXCOM G6 TRANSMITTER$8,542
- InPen$6,100
- FreeStyle Libre Pro$4,950
- CeQur Simplicity$4,950
- Minimed 670G System$4,715
- Minimed 630G$3,188
- FreeStyle Libre 2$1,704
- FreeStyle Libre$328
- Minimed 770G System$250
How this compares
$349,259 in reported general payments places this provider in the 95th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 251 | $365,954 |
| MounjaroTirzepatide | 206 | $240,222 |
| FarxigaDapagliflozin Propanediol | 166 | $166,483 |
| TrulicityDulaglutide | 106 | $131,489 |
| Tresiba Flextouch U-200Insulin Degludec | 89 | $88,189 |
| JardianceEmpagliflozin | 82 | $82,875 |
| KerendiaFinerenone | 65 | $66,301 |
| InvokanaCanagliflozin | 67 | $58,111 |
| Tresiba Flextouch U-100Insulin Degludec | 104 | $55,939 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $55,824 |
| RybelsusSemaglutide | 17 | $48,095 |
| ForteoTeriparatide | 12 | $45,528 |
| Novolog FlexpenInsulin Aspart | 143 | $43,630 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 55 | $43,067 |
| TymlosAbaloparatide | 15 | $37,709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo | $28 | $417,239324 claims |
| Novo NordiskOzempic, Rybelsus | $169,752 | $414,049268 claims |
| AstraZenecaFarxiga | $40,727 | $166,483166 claims |
| Boehringer IngelheimJardiance | $11 | $82,87582 claims |
| BayerKerendia | $25,994 | $66,30165 claims |
| Johnson & JohnsonInvokana | $13,839 | $58,11167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Eau Claire
- Marita FisherEau Claire$2K
- Kent RayEau Claire$2K
- Odette MorganEau Claire$466
- Neil BinkleyMadison$556K
- Anoop Mohamed IqbalGreenfield$405K
- Adriana IoachimescuMilwaukee$370K
- Steven RabinoweRacine$344K
- Daniel Shortla Crosse$328K
- Laura AndrewsMenasha$294K
- Amy DeguemeMequon$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.